• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

使用213Bi的靶向α治疗。

Targeted alpha therapy with 213Bi.

作者信息

Morgenstern Alfred, Bruchertseifer Frank, Apostolidis Christos

机构信息

European Commission, Joint Research Centre, Institute for Transuranium Elements, PO Box 2340, 76125 Karlsruhe, Germany.

出版信息

Curr Radiopharm. 2011 Oct;4(4):295-305. doi: 10.2174/1874471011104040295.

DOI:10.2174/1874471011104040295
PMID:22202152
Abstract

The potential of targeted therapy with the alpha emitter 213Bi has been successfully demonstrated in a large number of preclinical studies and several clinical trials have provided evidence for its feasibility, safety and therapeutic efficacy. This review describes methods for the production of 225Ac and 225Ac/213Bi radionuclide generators, gives an overview of selected preclinical studies and summarizes the current clinical experience with 213Bi.

摘要

α发射体213Bi靶向治疗的潜力已在大量临床前研究中得到成功证明，多项临床试验也为其可行性、安全性和治疗效果提供了证据。本综述描述了225Ac和225Ac/213Bi放射性核素发生器的生产方法，概述了选定的临床前研究，并总结了目前213Bi的临床经验。

相似文献

1
Targeted alpha therapy with 213Bi.使用213Bi的靶向α治疗。
Curr Radiopharm. 2011 Oct;4(4):295-305. doi: 10.2174/1874471011104040295.
2
An Overview of Targeted Alpha Therapy with Actinium and Bismuth.锕和铋靶向α治疗概述
Curr Radiopharm. 2018;11(3):200-208. doi: 10.2174/1874471011666180502104524.
3
Bismuth-213 and actinium-225 -- generator performance and evolving therapeutic applications of two generator-derived alpha-emitting radioisotopes.铋 - 213和锕 - 225——两种基于发生器产生的α发射性放射性同位素的发生器性能及不断发展的治疗应用
Curr Radiopharm. 2012 Jul;5(3):221-7. doi: 10.2174/1874471011205030221.
4
Clinical Studies with Bismuth-213 and Actinium-225 for Hematologic Malignancies.铋 - 213和锕 - 225用于血液系统恶性肿瘤的临床研究
Curr Radiopharm. 2018;11(3):192-199. doi: 10.2174/1874471011666180525102814.
5
An 225Ac/213Bi generator system for therapeutic clinical applications: construction and operation.一种用于治疗性临床应用的225Ac/213Bi发生器系统：构建与运行。
Appl Radiat Isot. 1999 May;50(5):895-904. doi: 10.1016/s0969-8043(98)00151-1.
6
Which radionuclide, carrier molecule and clinical indication for alpha-immunotherapy?α免疫疗法使用的是哪种放射性核素、载体分子以及临床适应症？
Q J Nucl Med Mol Imaging. 2015 Jun;59(2):161-7. Epub 2015 Mar 10.
7
Challenges and opportunities in developing Actinium-225 radiopharmaceuticals.开发锕-225 放射性药物的挑战与机遇。
Nucl Med Commun. 2022 Sep 1;43(9):970-977. doi: 10.1097/MNM.0000000000001594. Epub 2022 Jun 23.
8
Progress in Targeted Alpha-Particle Therapy. What We Learned about Recoils Release from In Vivo Generators.靶向 α 粒子治疗的进展。我们从体内发生器中了解到的放射性核素发射。
Molecules. 2018 Mar 5;23(3):581. doi: 10.3390/molecules23030581.
9
Breakthrough of 225Ac and its radionuclide daughters from an 225Ac/213Bi generator: development of new methods, quantitative characterization, and implications for clinical use.225Ac及其放射性核素子体从225Ac/213Bi发生器的突破：新方法的开发、定量表征及其临床应用意义。
Appl Radiat Isot. 2001 Nov;55(5):667-78. doi: 10.1016/s0969-8043(01)00062-8.
10
Applications of 211At and 223Ra in targeted alpha-particle radiotherapy.211砹和223镭在靶向α粒子放射治疗中的应用。
Curr Radiopharm. 2011 Oct;4(4):283-94. doi: 10.2174/1874471011104040283.

引用本文的文献

1
Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists.使用锕-225标记的生长抑素受体激动剂和拮抗剂的α肽受体放射性核素治疗
Front Med (Lausanne). 2022 Dec 7;9:1034315. doi: 10.3389/fmed.2022.1034315. eCollection 2022.
2
Targeted α-Therapy in Cancer Management: Synopsis of Preclinical and Clinical Studies.靶向 α 治疗在癌症管理中的应用：临床前和临床研究综述。
Cancer Biother Radiopharm. 2020 Sep;35(7):475-484. doi: 10.1089/cbr.2019.3340. Epub 2020 Mar 23.
3
Development of Targeted Alpha Particle Therapy for Solid Tumors.
针对实体瘤的靶向 alpha 粒子治疗的发展。
Molecules. 2019 Nov 26;24(23):4314. doi: 10.3390/molecules24234314.
4
Therapeutic Radiometals: Worldwide Scientific Literature Trend Analysis (2008⁻2018).治疗性放射性金属：全球科学文献趋势分析（2008-2018 年）。
Molecules. 2019 Feb 12;24(3):640. doi: 10.3390/molecules24030640.
5
Targeted α-therapy of prostate cancer using radiolabeled PSMA inhibitors: a game changer in nuclear medicine.使用放射性标记的前列腺特异性膜抗原（PSMA）抑制剂对前列腺癌进行靶向α治疗：核医学领域的变革者。
Am J Nucl Med Mol Imaging. 2018 Aug 20;8(4):247-267. eCollection 2018.
6
Efficient formation of inert Bi-213 chelates by tetraphosphorus acid analogues of DOTA: towards improved alpha-therapeutics.通过DOTA的四磷酸类似物高效形成惰性Bi-213螯合物：迈向改进的α疗法。
EJNMMI Res. 2018 Aug 8;8(1):78. doi: 10.1186/s13550-018-0431-3.
7
An Overview of Targeted Alpha Therapy with Actinium and Bismuth.锕和铋靶向α治疗概述
Curr Radiopharm. 2018;11(3):200-208. doi: 10.2174/1874471011666180502104524.
8
Alpha-Emitters and Targeted Alpha Therapy in Oncology: from Basic Science to Clinical Investigations.《放射治疗学中的 α 发射器和靶向 α 治疗：从基础科学到临床研究》
Target Oncol. 2018 Apr;13(2):189-203. doi: 10.1007/s11523-018-0550-9.
9
Influence of tumour size on the efficacy of targeted alpha therapy with (213)Bi-[DOTA(0),Tyr(3)]-octreotate.肿瘤大小对（213）Bi-[DOTA(0),Tyr(3)]-奥曲肽靶向α治疗疗效的影响
EJNMMI Res. 2016 Dec;6(1):6. doi: 10.1186/s13550-016-0162-2. Epub 2016 Jan 20.
10
Fractionated intravesical radioimmunotherapy with (213)Bi-anti-EGFR-MAb is effective without toxic side-effects in a nude mouse model of advanced human bladder carcinoma.在晚期人类膀胱癌裸鼠模型中，采用（213）Bi-抗表皮生长因子受体单克隆抗体进行膀胱内分次放射免疫治疗有效且无毒性副作用。
Cancer Biol Ther. 2015;16(10):1526-34. doi: 10.1080/15384047.2015.1071735. Epub 2015 Jul 15.